Howard S. Hochster, MD, provides insight into TAS-102 (trifluridine/tipiracil; Lonsurf) and highlights other important research being conducted in the colorectal cancer space.
Ana Acuna-Villaorduna, MD, provides further insight into the study that compares age and race as factors for the incidence of early-onset colorectal cancer.
Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.
Sujatha Nallapareddy, MD, discusses how personalized therapy has improved the outlook for patients with colorectal cancer and sheds light on some of the challenges that lie ahead.
Christopher Lieu, MD, highlights updates on biomarker-directed therapy with colorectal cancer and ongoing research being done with immunotherapy.
Wells A. Messersmith, MD, discusses the evolving standards of care in colorectal cancer and the importance of molecular testing in guiding treatment decisions.
Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.
The triplet regimen of encorafenib, binimetinib, and cetuximab led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E-mutant metastatic colorectal cancer who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.
With multiple biomarker-directed clinical trials for metastatic CRC expected to produce data within the next few years, experts in gastrointestinal oncology who took part in a recent OncLive Peer Exchange® program recommended that clinicians become more proactive about incorporating genomic and immune markers into their decision making.
Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.